Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT06933992

Safety and Efficacy of Chocolate Balloon Catheter in Peripheral Arterial Disease (CHOCO-PAD)

Evaluation of the Safety and Efficacy of the Chocolate Balloon Catheter in Percutaneous Transluminal Angioplasty (PTA) for Peripheral Arterial Disease (PAD): A Prospective, Multicenter, Single-Arm Observational Trial

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
171 (estimated)
Sponsor
First People's Hospital of Hangzhou · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study aims to learn about the long-term safety and effectiveness of the Chocolate Balloon Catheter in patients with blocked leg arteries (peripheral artery disease, or PAD). The Chocolate Balloon is a special type of balloon used during minimally invasive procedures to open narrowed arteries while potentially causing less damage to the blood vessel. The main question it aims to answer is: Does the Chocolate Balloon keep the treated artery open after 12 months without needing repeat procedures? Patients with PAD who are already scheduled to undergo an artery-opening procedure (angioplasty) with the Chocolate Balloon as part of their standard care will answer the question about the safety and effectiveness of the Chocolate Balloon Catheter

Conditions

Interventions

TypeNameDescription
DEVICEChocolate PTA Balloon CatheterThe Chocolate PTA balloon catheter is a nitinol-constrained percutaneous transluminal angioplasty balloon designed to minimize vessel trauma during treatment of peripheral arterial lesions. The device is used according to its standard indications and instructions for use in patients with symptomatic peripheral artery disease.

Timeline

Start date
2025-07-20
Primary completion
2027-07-20
Completion
2027-12-20
First posted
2025-04-18
Last updated
2025-04-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06933992. Inclusion in this directory is not an endorsement.